...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression.
【24h】

BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression.

机译:肾脏同种异体移植受体中的BK病毒相关性肾病:基于西罗莫司的免疫抑制的抢救治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND.: BK virus nephritis (BKN) in recipients of renal allografts has reemerged during the past 5 years. Despite increased incidence, therapeutic options remain limited and progression of the disease often leads to allograft failure. METHODS.: From May 2002 to July 2002, we performed protocol biopsies in 25 recipients of kidney allografts with progressive allograft dysfunction; three patients demonstrated unexpected histopathologic features of BKN. We tested the hypothesis that replacement of their lymphocytotoxic and nephrotoxic immunosuppression (combination of mycophenolate and tacrolimus) with sirolimus- and prednisone-based therapy can lead to disappearance of the virus without increasing the risk of acute rejection. RESULTS.: During the median follow-up of 18 months after sirolimus and prednisone therapy, decoy cells disappeared first, followed by progressive decrease in the median plasma BK virus-DNA load, and undetectable levels at the last follow-up. Patients remained free of acute rejection, and follow-up median estimated creatinine clearance increased to 67 mL/min (range 62-75 mL/min) from 52 mL/min (range 51-54 mL/min) at the time of diagnosis. CONCLUSIONS.: Further studies are needed, but at present these preliminary results offer a new direction for therapeutic intervention in recipients of renal allografts with BKN.
机译:背景:在过去的5年中,同种异体肾移植受者的BK病毒性肾炎(BKN)再次出现。尽管发病率增加,但是治疗选择仍然有限,并且疾病的进展常常导致同种异体移植失败。方法:从2002年5月至2002年7月,我们对25名进行性同种异体移植功能障碍的肾脏同种异体移植患者进行了协议活检。三名患者表现出意想不到的BKN的组织病理学特征。我们检验了以下假设:用基于西罗莫司和泼尼松的疗法替代其淋巴细胞毒性和肾毒性免疫抑制(霉酚酸酯和他克莫司的组合)可以导致病毒消失,而不会增加急性排斥的风险。结果:在西罗莫司和泼尼松治疗后的18个月的中位随访期间,诱饵细胞首先消失,随后血浆BK病毒DNA的中位数逐渐下降,在最后一次随访中未检测到水平。患者仍然没有急性排斥反应,随访时估计的肌酐清除率中值从诊断时的52 mL / min(范围51-54 mL / min)增加到67 mL / min(范围62-75 mL / min)。结论:需要进一步的研究,但目前,这些初步结果为肾移植同种异体移植受体的治疗提供了新的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号